Valuations in healthcare space continue to be excessive across Asia: Abrar Mir, Quadria Capital

Abrar Mir, Managing Partner and Co-Founder of Quadria Capital

Indian drug makers, whose business models have been under pressure as revenues from the US generic market grow at a slower pace, will have to move away from playing the cost game and focus on innovation to move to the next level, and the potential for innovation offers a bright future for these companies, says Abrar Mir, managing partner, Quadria Capital Investment Management Pte. Ltd, the Singapore- and India-based private equity (PE) firm that focuses on healthcare.

Continue reading this story with a subscription to DealStreetAsia.

Subscribe